Healthcare provider profile · identity verified

John Y. Wang, MD

Internal Medicine · LOS ANGELES, CA · NPI 1457410078

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	984	321
Amlodipine Besylate	Amlodipine Besylate	529	192
Losartan Potassium	Losartan Potassium	311	112
Rosuvastatin Calcium	Rosuvastatin Calcium	286	107
Potassium Chloride	Potassium Chloride	283	101
Metformin Hcl Er	Metformin Hcl	232	90
Hydrochlorothiazide	Hydrochlorothiazide	220	77
Lisinopril	Lisinopril	209	73
Metformin Hcl	Metformin Hcl	193	66
Gabapentin	Gabapentin	182	78
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	182	57
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	181	49
Glipizide	Glipizide	173	65
Levothyroxine Sodium	Levothyroxine Sodium	153	46
Omeprazole	Omeprazole	139	60
Furosemide	Furosemide	138	58
Metoprolol Tartrate	Metoprolol Tartrate	136	52
Tamsulosin Hcl	Tamsulosin Hcl	136	54
Atenolol	Atenolol	130	42
Albuterol Sulfate Hfa	Albuterol Sulfate	126	57
Pradaxa	Dabigatran Etexilate Mesylate	121	32
Ozempic	Semaglutide	104	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	101	33
Pantoprazole Sodium	Pantoprazole Sodium	101	36
Terazosin Hcl	Terazosin Hcl	101	38
Trazodone Hcl	Trazodone Hcl	100	40
Meloxicam	Meloxicam	96	53
Pravastatin Sodium	Pravastatin Sodium	88	29
Jardiance	Empagliflozin	86	29
Ezetimibe	Ezetimibe	83	29
Triamcinolone Acetonide	Triamcinolone Acetonide	83	47
Alendronate Sodium	Alendronate Sodium	75	24
Bisoprolol Fumarate	Bisoprolol Fumarate	71	23
Simvastatin	Simvastatin	67	24
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	62	16
Clopidogrel	Clopidogrel Bisulfate	60	19
Tramadol Hcl	Tramadol Hcl	60	13
Spironolactone	Spironolactone	57	21
Prednisone	Prednisone	55	43
Ondansetron Odt	Ondansetron	54	15
Famotidine	Famotidine	51	27
Eliquis	Apixaban	50	15
Ibuprofen	Ibuprofen	49	23
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	47	17
Finasteride	Finasteride	46	15
Lorazepam	Lorazepam	44	14
Lactulose	Lactulose	42	11
Alvesco	Ciclesonide	40	18
Wixela Inhub	Fluticasone Propion/Salmeterol	40	14
Zolpidem Tartrate	Zolpidem Tartrate	40	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	36	36
Allopurinol	Allopurinol	35	12
Lovastatin	Lovastatin	35	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	34	16
Ketoconazole	Ketoconazole	34	21
Metoprolol Succinate	Metoprolol Succinate	31	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	30	suppressed
Benazepril Hcl	Benazepril Hcl	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	11
Chlorthalidone	Chlorthalidone	27	suppressed
Colchicine	Colchicine	27	suppressed
Azelastine Hcl	Azelastine Hcl	25	suppressed
Azithromycin	Azithromycin	25	23
Carvedilol	Carvedilol	25	11
Mirtazapine	Mirtazapine	25	suppressed
Naproxen	Naproxen	25	suppressed
Sertraline Hcl	Sertraline Hcl	25	15
Digoxin	Digoxin	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Alprazolam	Alprazolam	23	suppressed
Humulin N	Insulin Nph Human Isophane	23	11
Hydrocortisone	Hydrocortisone	23	11
Cephalexin	Cephalexin	21	20
Ciclopirox	Ciclopirox	21	12
Doxycycline Monohydrate	Doxycycline Monohydrate	21	21
Fluconazole	Fluconazole	21	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	suppressed
Nystatin	Nystatin	21	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	20	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	20	13
Montelukast Sodium	Montelukast Sodium	20	suppressed
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Topiramate	Topiramate	20	suppressed
Acyclovir	Acyclovir	19	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Fluocinonide	Fluocinonide	17	11
Trospium Chloride	Trospium Chloride	17	suppressed
Baclofen	Baclofen	16	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	15	14
Fenofibrate	Fenofibrate	15	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	15	suppressed
Amoxicillin	Amoxicillin	14	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Naloxone Hcl	Naloxone Hcl	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Victoza 2-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error